The CEO of Abbott Laboratories warns the customs tariff here to remain, as it indicates new American investments

Abbott laboratories (AbhorIt prepares for the impact of high definitions, including the US tax by 50 % on its Indian imports.

“Our impact between the entire network is just less than $ 200 million,” CEO Robert Ford said in the opening presentation of Yahoo Finance (the video above). “But I think the main thing here, which is one thing we learned, is that the tariff is once, whether in the United States or in another country, does not disappear.”

Ford added that the healthcare company finds ways to alleviate the definitions, including conducting long -term investments in manufacturing and supply chains.

Read more: 5 ways to leak your financial tariff

Illinois -based ABBOTT has about 90 manufacturing sites worldwide, with nearly 40 in the United States, for each Ford. The Trump administration has launched a definition, including 50 % in India, a major pharmaceutical product.

He said: “A very large percentage of our American revenues is supported by the United States, and our international revenues support international manufacturing sites.” This strategy helps to store the company from foreign exchange fluctuations, but it builds the elasticity of the supply chain.

In April, Abbott announced an investment of $ 500 million to enhance American manufacturing in two manufacturers in Illinois and Texas. These sites are expected to be “escalating and operating by the end of the year,” according to Ford.

Earlier this month, the company revealed plans for a new cardiovascular manufacturing site in Georgia. Before that, she said she would build a food products facility in Ohio.

These expansion plans come as Abbot published the results of the second quarter of the steel. I reported revenues of $ 11.14 billion, amounting to $ 11.07 billion, and average profits per share of $ 1.26, compared to unanimity estimates of $ 1.25, according to Bloomberg data.

However, the ABBOTT tariffs pushed its EPS guidelines. The company now expects profits per share from $ 5.10 to $ 5.20, which is a slight review of Previous appreciation From $ 5.05 to $ 5.25.

While Abbot’s investments were not only driven by commercial concerns, Ford admitted the changing economic background.

“We have always had a philosophy to align our request with our production,” Ford said. “Therefore, he is really thinking about a much larger context. It is not necessarily driven by definitions, but it really relates to the cost of our cost structure with our revenue structure.”

Separately, Abbott is trying to treat urgent blood shortages in the United States, which has decreased to its lowest levels in decades. The company has partnered with the Big Ten conference to increase blood donations from students, graduates and fans.